Image pharmaphorum Editor R&D A lifeline for rare disease patients For more than 25 years Alexion has been blazing a trail in rare diseases, bringing a series of life-changing medicines to market. R&D Living with LHON: Adapting to sight loss at 15 years old When faced with a devastating diagnosis, a family has two choices – to give up or make it their mission to adapt and carry on. R&D How pharma can support doctors who treat rare diseases Where do doctors see patients with rare diseases, how do they keep up with treatment advances and what can pharmaceutical companies do to help? R&D The patient perspective on advocacy Growing up with the shadow of Huntington’s disease (HD) means Seth Rotberg understands the importance of peer support and credible information. Load more results
R&D A lifeline for rare disease patients For more than 25 years Alexion has been blazing a trail in rare diseases, bringing a series of life-changing medicines to market.
R&D Living with LHON: Adapting to sight loss at 15 years old When faced with a devastating diagnosis, a family has two choices – to give up or make it their mission to adapt and carry on.
R&D How pharma can support doctors who treat rare diseases Where do doctors see patients with rare diseases, how do they keep up with treatment advances and what can pharmaceutical companies do to help?
R&D The patient perspective on advocacy Growing up with the shadow of Huntington’s disease (HD) means Seth Rotberg understands the importance of peer support and credible information.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.